Ardelyx (ARDX) Q3 2026 earnings review
Ardelyx holds its lowered IBSRELA plan, but XPHOZAH sales dip
Ardelyx, the maker of bowel drug IBSRELA and kidney pill XPHOZAH, steadied its main medicine while its second product slipped. Total product revenue rose 19% from a year ago to $125 million as IBSRELA grew 23%. Chief executive Mike Raab kept the full-year outlook unchanged, which by our math leaves IBSRELA growing 24% in the fourth quarter. The drugmaker also finished recruiting patients early for a Phase 3 study in chronic constipation.
| IBSRELA revenue | $96.3M +23% from a year ago |
|---|---|
| XPHOZAH revenue | $29.2M -9% from last quarter |
| Net loss | $0.7M $1.0M loss a year ago |
| Full-year revenue outlook | Unchanged IBSRELA $350–370M; XPHOZAH $110–120M |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because meeting a lowered target after last quarter's cut only stops the bleeding. Holding the plan removes the immediate risk of a second downgrade, and a new patent extends formulation protection to 2041. One caution: XPHOZAH sales fell 9% from last quarter, and insurance hurdles forced Ardelyx to spend 12% more on sales and overhead while its $1 billion IBSRELA goal remains without a target date.
The question now is whether television ads and reimbursement staff can lift new patient starts without rebates that cut the net price per bottle. Either those commercial investments re-accelerate prescription growth in 2027, or Ardelyx must give insurers price discounts that eat into the volume gains. The gross-to-net discount rate in the quarterly filing and fourth-quarter IBSRELA sales will tell.
🐂 Bull Case
IBSRELA Stabilizes on the Reset Plan
IBSRELA is Ardelyx's pill for irritable bowel syndrome with constipation, and it brings in three-quarters of product sales. Last quarter the drugmaker cut its full-year outlook for the medicine by 14% after health insurers added prior-authorization hurdles. This quarter chief executive Mike Raab held the lowered $350–370 million target and avoided a second cut.
- Q3 IBSRELA sales: $96.3 million, up 23.2% from a year ago and up 11.6% from last quarter
- Total revenue: $127.7 million, up 15.7% from a year ago, or 19.4% by our math excluding last year's $3.4 million Japan milestone
- Implied Q4 IBSRELA sales: $107.4 million at the middle of the range, up 24.0% from a year ago by our math
The quarter landed right on the $92–100 million pace implied by the lowered outlook, because prescription refills and doctor adoption kept rising. Holding the target eases the fear of another reset this year, though full-year growth still steps down from 73% last year to about 31%.
What to watch: fourth-quarter IBSRELA sales against the $107.4 million needed to reach the middle of the full-year plan. A reading above that mark would show the new television ads and reimbursement team are lifting new patient starts before the first-quarter deductible reset.
Constipation Trial Finishes Enrollment Early
Ardelyx wants to sell tenapanor, the active ingredient in IBSRELA, to a wider group of patients who suffer from chronic idiopathic constipation (CIC), or ongoing constipation with no known cause. The company originally planned to finish signing up roughly 700 adults for its Phase 3 study, called ACCEL, by the end of 2026.
This quarter the drugmaker "completed enrollment ahead of schedule in its Phase 3 clinical trial, ACCEL, evaluating tenapanor for the treatment of chronic idiopathic constipation (CIC) in adults". Competing bowel drugs like Linzess and Trulance already hold approval for both conditions. Finishing recruitment early keeps the 26-week study on track for results in the second half of 2027.
What to watch: topline data from the ACCEL study in the second half of 2027. A positive readout would let Ardelyx apply for approval to market IBSRELA to chronic constipation patients without developing a separate pill.
New Formulation Patent Extends Protection to 2041
Pharmaceutical companies rely on patents to block cheap generic copies once a drug becomes profitable. Ardelyx already holds a formulation patent expiring in 2042, and management has emphasized its intellectual property as a pillar of its long-term value.
The US Patent and Trademark Office notified the biopharma group that on November 10, 2026, it will issue Patent No. 12,788,750, titled "Oral Formulation of a Therapeutic Compound". The new patent covers the commercial recipes for both IBSRELA and XPHOZAH through December 6, 2041. That adds another layer of legal defense beyond the core compound patents that expire in 2033 and 2034.
What to watch: any disclosure in the quarterly filing about generic drugmakers challenging these formulation patents. If rivals file applications to sell copies after 2034, Ardelyx will have to defend the 2041 and 2042 patents in court.
🐻 Bear Case
Payer Hurdles Keep Pushing Up Sales Costs
"IBSRELA year-over-year growth of 23% is the engine driving total product revenue of over $125 million for the quarter," chief executive Mike Raab said. Yet that engine has slowed for four straight quarters from 92% a year ago, and Ardelyx is spending heavily to work around insurance roadblocks that require patients to try cheaper drugs first.
Selling, general and administrative expenses — sales reps, marketing and overhead — rose 12.3% to $93.9 million for "deliberate investments to address the access barriers and drive future adoption of IBSRELA", including streaming television ads. Research and development costs jumped 39.5% to $25.2 million, rising 3.4 percentage points of revenue by our math, so operating profit fell from $4.7 million to $4.0 million.
Raab still promises $1 billion in annual IBSRELA sales, but for a second quarter the company gave no target year after putting its 2029 timetable under review. What to watch: whether the full-year 2027 outlook in February includes a new date for the $1 billion goal, because leaving it undated would show insurance hurdles have permanently slowed the growth curve.
XPHOZAH Shrinks From Last Quarter
XPHOZAH is Ardelyx's pill for lowering blood phosphorus in kidney dialysis patients. After losing Medicare drug coverage in January 2025 and losing a court appeal against the government in June 2026, the drug must rely on private and Medicaid insurers while Medicare patients receive free supply.
Sales of the kidney medicine fell 8.5% from last quarter to $29.2 million, and grew only 6.6% from a year ago after rising 27.4% in the second quarter. Management held the full-year outlook at $110–120 million, which by our math implies $30.6 million in the fourth quarter, still below the second-quarter peak of $31.9 million.
What to watch: fourth-quarter XPHOZAH revenue against the $30.6 million implied by the middle of the full-year plan. Another sequential drop would show the non-Medicare patient pool is nearing its ceiling after Ardelyx withdrew its $750 million peak target last quarter.
Inventory Keeps Rising Faster Than Sales
Ardelyx manufactures tenapanor through outside suppliers and built up raw materials and unfinished pills for its original, higher sales plan. Even after cutting its IBSRELA revenue outlook in August, the company continues to take in far more stock than patients use.
Inventory on the balance sheet climbed another 13.4% from last quarter to $157.6 million, up 28.0% since December, alongside $17.2 million in prepaid manufacturing. By contrast, the cost of goods sold in the third quarter was just $4.5 million. Stockpiling over eight years of current cost of sales ties up cash and risks future write-downs if shelf lives expire.
What to watch: the breakdown of current versus long-term inventory and purchase commitments in the quarterly filing. A further rise in unfinished stock would mean contract minimums still force Ardelyx to buy more supply than it can sell.
Risks this quarter didn't answer
Three standing concerns from last quarter cannot be checked in the earnings release or presentation and await the quarterly filing or conference call.
- Gross-to-net price discounts: rebates and channel fees took 34.0% of gross sales in Q2 against an earlier full-year target in the low 30s; the Q3 rate lives in the 10-Q filing.
- Payer rebate contracts: management signaled talks with insurers last quarter to ease prior authorizations, and any new rebate deals would raise discount rates.
- New patient starts vs refills: slide 6 says total scripts grew, but does not disclose whether new-patient starts recovered from Q2's slowdown.
💲 Other KPIs
Unpaid customer bills fell 6.9% from last quarter's $100.4 million, easing a first-half buildup that had seen receivables jump 39.7% between December and June. Collecting those bills helped lift cash even as inventory kept rising, though receivables remain 30.1% higher than at the end of 2025.
Total cash and marketable securities rose by $3.5 million from June and sits $20.6 million above year-end 2025. Because the June total included a $50 million loan draw, adding cash this quarter shows product sales covered day-to-day bills as net loss narrowed to $0.7 million.
The share count rose 3.3% from a year ago and 0.8% from last quarter. The drugmaker pays employees partly in stock — $15.1 million worth this quarter, up 18.9% from a year ago — which steadily increases the number of shares without any share buybacks to offset it.
🔮 Guidance
Unchanged. Management kept the lowered range it set in August, which calls for 31.3% full-year growth at the middle of the range. By our math, that leaves $97.4–117.4 million for Q4, or $107.4 million at the middle — up 24.0% from a year ago and up 11.5% from Q3. After cutting the range by $60 million in Q2, holding it keeps the year achievable.
Unchanged. The plan still points to 11.0% annual growth at the $115 million middle of the range. By our math, nine-month sales of $84.4 million leave $25.6–35.6 million for Q4, or $30.6 million at the middle — up 10.2% from a year ago and up 5.1% from Q3. It is the fourth straight quarter at this range.
Unchanged. Research and overhead spending remains capped below $500 million after management trimmed the ceiling from $520 million last quarter. With $369.1 million spent through September by our math, Q4 costs can reach up to $130.9 million, or 10.0% above Q3's $119.1 million, giving Ardelyx room to fund its new television campaign.
Unchanged. The company still targets $1 billion in peak annual sales for its bowel drug. However, after putting its original 2029 target date under review last quarter, management again gave no year for reaching the milestone.
❓ Key Questions
What was the gross-to-net discount rate in Q3?
Discounts and rebates took 34.0% of gross sales in Q2 and 35.0% in the first half, above the low-30s rate management once planned. The release omits the Q3 rate, which shows how much price Ardelyx gives up to get prescriptions filled.
Did Ardelyx sign new rebate contracts with insurers?
Last quarter management said prior-authorization hurdles merited new discussions with health plans, while Slide 6 says work continues to "eliminate the payor friction". Investors need to know if removing those hurdles requires paying rebates that reduce revenue per bottle.
Why did inventory jump another $19 million to $158 million?
Inventory rose 13.4% in Q3 to $157.6 million even though quarterly cost of sales was just $4.5 million and the IBSRELA sales plan is lower. Management has not said when raw-material purchases will slow to match actual prescription demand.
Where is the IND filing for next-generation drug RDX10531?
At the start of 2026 Ardelyx targeted a regulatory filing to begin human trials of RDX10531 in the second half of 2026. Slide 14 still lists "IND-enabling studies underway", leaving unclear whether the filing has slipped into 2027.